Via data derived various primary secondary healthcare settings able predict efficacy possible side effect medication way PHARMO Institute want contribute health innovation health optimization observational study diseasespecific cohort created various databases mission achieve greater insight real world healthcare collection expert analysis patientcentric information internal standardised procedure quality guideline accordance ENCePP Guide Methodological Standards Pharmacoepidemiology ENCePP Code Conduct wwwenceppeu guarantee high quality services performing pharmacoepidemiological study including project management methodology data quality stakeholder communication European level perform postauthorisation safety effectiveness study PASS  PAES drug utilisation study DUR study safety outcome many type study PHARMO Institute studying use effectiveness side effect medicines used daily practice many years use large file data million patient investigate often medicine le effective even cause side effects PHARMO Institute place turn need substantiated authoritative evidence Menu Dedicated research reallife healthcare PHARMO Institute PHARMO Institute dedicated study epidemiology drug utilization drug safety health outcomes independent research organization study effect drug treatment real life enhance health people using medication way contribute drug safety able find unwanted side effect advanceWe base study database derived general practitioners hospitals labs different disease related database in outpatient pharmacies anonymized STIZON used follow disease course effect medication treatment Via data derived various primary secondary healthcare settings able predict efficacy possible side effect medication way PHARMO Institute want contribute health innovation health optimization observational study diseasespecific cohort created various databases use data  million person year  Patients  Practices primary secondary care  Founded  PHARMO Institute independent research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources PHARMO Insitute developed maintains large high quality Database Network work closely international medical university European databases study longitudinal real world patient data PHARMO Institute contributes risk management outcome research provides solution decisionmakers market access health economics health outcome domainsOur mission achieve greater insight real world healthcare collection expert analysis patientcentric information News update Read latest update publication news section below See Halifax ICPE  proud Gold sponsor year look forward seeing PHARMO Institute Lumanity Partnering Invest new Solutions Support Enhanced Real World Data Analytics pleased announce Myocarditis pericarditis associated SARSCoV vaccine Together colleague across Europe recently published work entitled Myocarditis pericarditis associated SARSCoV Members information question suggestion services Please hesitate get touch u via button below fill contact form contact page look forward hearing you Founded  PHARMO Institute independent scientific research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources Links Navigate Contact PHARMO InstituteVan Deventerlaan  AE UtrechtThe Netherlands     pharmopharmonl Menu Dedicated research reallife healthcare PHARMO Institute PHARMO Institute dedicated study epidemiology drug utilization drug safety health outcomes independent research organization study effect drug treatment real life enhance health people using medication way contribute drug safety able find unwanted side effect advanceWe base study database derived general practitioners hospitals labs different disease related database in outpatient pharmacies anonymized STIZON used follow disease course effect medication treatment Via data derived various primary secondary healthcare settings able predict efficacy possible side effect medication way PHARMO Institute want contribute health innovation health optimization observational study diseasespecific cohort created various databases use data  million person year  Patients  Practices primary secondary care  Founded  PHARMO Institute independent research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources PHARMO Insitute developed maintains large high quality Database Network work closely international medical university European databases study longitudinal real world patient data PHARMO Institute contributes risk management outcome research provides solution decisionmakers market access health economics health outcome domainsOur mission achieve greater insight real world healthcare collection expert analysis patientcentric information News update Read latest update publication news section below See Halifax ICPE  proud Gold sponsor year look forward seeing PHARMO Institute Lumanity Partnering Invest new Solutions Support Enhanced Real World Data Analytics pleased announce Myocarditis pericarditis associated SARSCoV vaccine Together colleague across Europe recently published work entitled Myocarditis pericarditis associated SARSCoV Members information question suggestion services Please hesitate get touch u via button below fill contact form contact page look forward hearing you Founded  PHARMO Institute independent scientific research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources Links Navigate Contact PHARMO InstituteVan Deventerlaan  AE UtrechtThe Netherlands     pharmopharmonl Menu Dedicated research reallife healthcare PHARMO Institute PHARMO Institute dedicated study epidemiology drug utilization drug safety health outcomes independent research organization study effect drug treatment real life enhance health people using medication way contribute drug safety able find unwanted side effect advanceWe base study database derived general practitioners hospitals labs different disease related database in outpatient pharmacies anonymized STIZON used follow disease course effect medication treatment Via data derived various primary secondary healthcare settings able predict efficacy possible side effect medication way PHARMO Institute want contribute health innovation health optimization observational study diseasespecific cohort created various databases use data  million person year  Patients  Practices primary secondary care  Founded  PHARMO Institute independent research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources PHARMO Insitute developed maintains large high quality Database Network work closely international medical university European databases study longitudinal real world patient data PHARMO Institute contributes risk management outcome research provides solution decisionmakers market access health economics health outcome domainsOur mission achieve greater insight real world healthcare collection expert analysis patientcentric information News update Read latest update publication news section below See Halifax ICPE  proud Gold sponsor year look forward seeing PHARMO Institute Lumanity Partnering Invest new Solutions Support Enhanced Real World Data Analytics pleased announce Myocarditis pericarditis associated SARSCoV vaccine Together colleague across Europe recently published work entitled Myocarditis pericarditis associated SARSCoV Members information question suggestion services Please hesitate get touch u via button below fill contact form contact page look forward hearing you Founded  PHARMO Institute independent scientific research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources Links Navigate Contact PHARMO InstituteVan Deventerlaan  AE UtrechtThe Netherlands     pharmopharmonl Menu Expertise expertiseThe expert PHARMO Institute perform tailormade observational research using real world data help client effectively bridge gap clinical trial data real world evidence staff consists academically trained specialist epidemiology pharmacotherapeutics medicine informatics PHARMO Institutes inhouse expert performing pharmacoepidemiological study including project management methodology data quality stakeholder communication European level perform  and many PHARMO Institute us collection management analysis inhouse data source well data source partners lead European study provide critical evidence context emerging standard study design database analysis operations quality assurance EuropePHARMO Institute adheres high standard throughout research process based robust methodologies transparency scientific independence internal standardised procedure quality guideline accordance ENCePP Guide Methodological Standards Pharmacoepidemiology ENCePP Code Conduct  guarantee high quality services use data  million person year  Patients  Practices primary secondary care  Data access time information question suggestion services Please hesitate get touch u via button below fill contact form contact page look forward hearing you Founded  PHARMO Institute independent scientific research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources Links Navigate Contact PHARMO InstituteVan Deventerlaan  AE UtrechtThe Netherlands     pharmopharmonl use cooky ensure give best experience website continue use site assume happy it Menu PHARMO Data PHARMO DataThe longitudinal nature data PHARMO Institute ha access to enables followup  million person welldefined population Netherlands average twelve years Currently  million active person  million inhabitant Netherlands captured Data collection period catchment area overlap data source differ Therefore final cohort size study depend data source included data source linked annual basis average lag time data one year electronic patient record include information age sex socioeconomic status mortality available information depends data source use data  million person year  Patients  Practices primary secondary care  Data access Data source PHARMO Institute ha access studyspecific datasets derived network electronic healthcare database encompassing anonymous data different primary secondary healthcare setting Netherlands different data source linked patient level validated algorithms ensure privacy data collection processing linkage anonymisation data performed STIZON STIZON independent ISOIEC  certified foundation act Trusted Third Party TTP data source PHARMO Institute information question suggestion services Please hesitate get touch u via button below fill contact form contact page look forward hearing you Founded  PHARMO Institute independent scientific research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources Links Navigate Contact PHARMO InstituteVan Deventerlaan  AE UtrechtThe Netherlands     pharmopharmonl Menu International collaboration International collaborationsWe collaborate database expert multicountry database study principle European Networkof Centres Pharmacoepidemiology  Pharmacovigilance  dedicated excellence research adhering ENCePP Guide Methodological Standards promoting scientific independence transparency registered study theEU PAS register publicly accessible resource registration pharmacoepidemiological pharmacovigilance studies SIGMA Consortium SIGMA Consortium contractbased alliance European Network Centres Pharmacoepidemiology Pharmacovigilance ENCePP research centre proven institutional pharmacoepidemiologic realworld evidence PERWE experience providing onestop shop research services best goto organisation comprehensive rigorous methodological research launched enable multicountry study use common analysis study response treatment large populationsSpecifically SIGMA Consortium conduct following activitiesAct trusted hub planning design contracting analyses delivery interpretation dissemination European PERWE studies providing onestop shop entity request research servicesProvide training education participation studiesPromote conduct facilitate innovative methodological researchThe SIGMA Consortium provide best evidence use benefit harm medications vaccine device improve public health patient care mission provide trusted pharmacoepidemiologic realworld evidence PERWE European federated professional network excellence based ENCePP Code Conduct information question suggestion services Please hesitate get touch u via button below fill contact form contact page look forward hearing you Founded  PHARMO Institute independent scientific research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources Links Navigate Contact PHARMO InstituteVan Deventerlaan  AE UtrechtThe Netherlands     pharmopharmonl use cooky ensure give best experience website continue use site assume happy it Menu Resource Library Recent study suggest woman susceptible diureticinduced hyponatremia resulting hospital admission men aim study wa confirm whether sex difference hyponatremia related hospital admission diuretic user remain adjusting several confounding variable age dose concurrent medication  September  high degree adherence direct oral anticoagulant essential reducing risk ischaemic stroke systemic embolism patient atrial fibrillation owing rapid decline anticoagulation activity dos omitted ie rebound effect  September  Due established teratogenicity valproates EU risk minimisation measure RMMs pregnancy prevention programme PPP valproate updated March   June  GPs shown important provider medical care pregnancy however little evidence exists awareness pregnancy prescribing medication women AIM ass GPs awareness pregnancy association prescribing medication potential safety risks  June  need updated incidence rate IRs Lyme borreliosis LB Europe including Netherlands estimated LB IRs stratified geographic area year age sex immunocompromised status socioeconomic status SES  April  COVID pandemic ha large impact worldwide known particularly affect older population paper outline protocol external validation prognostic model predicting mortality risk presentation COVID older population prognostic model originally developed adult population validated older population   year age three healthcare settings hospital setting primary care setting nursing home setting  April  largescale COVID vaccination campaign   led rapid increase number received adverse event report spontaneous reporting systems background incidence naturally occurring medical event became increasingly relevant causality assessment potential association vaccines novel approach signal detection wa warranted OE method useful approach signal detection potential adverse reaction handling large number ICSRs research needed attest causality clinical basis  March  Lowdose rivaroxaban ha indicated management atherosclerotic cardiovascular disease ASCVD recent  update European guidelines aimed describe prescription trend lowdose rivaroxaban ASCVD patient period  two European countries compare trend guideline changes determine characteristic user  March  safety effectiveness rivaroxaban versus vitamin K antagonist standard care SOC stroke prevention patient nonvalvular atrial fibrillation NVAF wa evaluated Europe Observational study conducted UK Netherlands Germany Sweden Primary safety outcome hospitalization intracranial hemorrhage gastrointestinal bleeding urogenital bleeding among new user rivaroxaban SOC NVAF outcome analyzed using cohort rivaroxaban SOC use nested casecontrol design current v nonuse Statistical analysis comparing rivaroxaban SOC cohort performed  February  Patient characteristic new rivaroxaban user nonvalvular atrial fibrillation changed   change differed countries pattern methodological implications considered interpretation observational study comparing effectiveness safety oral anticoagulants especially regarding potential bias due unmeasured confounding  February  Page Filter Therapeutic area Type study information question suggestion services Please hesitate get touch u via button below fill contact form contact page look forward hearing you Founded  PHARMO Institute independent scientific research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources Links Navigate Contact PHARMO InstituteVan Deventerlaan  AE UtrechtThe Netherlands     pharmopharmonl use cooky ensure give best experience website continue use site assume happy it Menu Contact u Contact PHARMO InstituteIf question research services please hesitate get touch usThe PHARMO InstituteVan Deventerlaan  AE UtrechtThe NetherlandsT E English versionDutch version information question suggestion services Please hesitate get touch u via button below fill contact form contact page look forward hearing you Founded  PHARMO Institute independent scientific research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources Links Navigate Contact PHARMO InstituteVan Deventerlaan  AE UtrechtThe Netherlands     pharmopharmonl Menu Resource Library Recent study suggest woman susceptible diureticinduced hyponatremia resulting hospital admission men aim study wa confirm whether sex difference hyponatremia related hospital admission diuretic user remain adjusting several confounding variable age dose concurrent medication  September  high degree adherence direct oral anticoagulant essential reducing risk ischaemic stroke systemic embolism patient atrial fibrillation owing rapid decline anticoagulation activity dos omitted ie rebound effect  September  Due established teratogenicity valproates EU risk minimisation measure RMMs pregnancy prevention programme PPP valproate updated March   June  GPs shown important provider medical care pregnancy however little evidence exists awareness pregnancy prescribing medication women AIM ass GPs awareness pregnancy association prescribing medication potential safety risks  June  need updated incidence rate IRs Lyme borreliosis LB Europe including Netherlands estimated LB IRs stratified geographic area year age sex immunocompromised status socioeconomic status SES  April  COVID pandemic ha large impact worldwide known particularly affect older population paper outline protocol external validation prognostic model predicting mortality risk presentation COVID older population prognostic model originally developed adult population validated older population   year age three healthcare settings hospital setting primary care setting nursing home setting  April  largescale COVID vaccination campaign   led rapid increase number received adverse event report spontaneous reporting systems background incidence naturally occurring medical event became increasingly relevant causality assessment potential association vaccines novel approach signal detection wa warranted OE method useful approach signal detection potential adverse reaction handling large number ICSRs research needed attest causality clinical basis  March  Lowdose rivaroxaban ha indicated management atherosclerotic cardiovascular disease ASCVD recent  update European guidelines aimed describe prescription trend lowdose rivaroxaban ASCVD patient period  two European countries compare trend guideline changes determine characteristic user  March  safety effectiveness rivaroxaban versus vitamin K antagonist standard care SOC stroke prevention patient nonvalvular atrial fibrillation NVAF wa evaluated Europe Observational study conducted UK Netherlands Germany Sweden Primary safety outcome hospitalization intracranial hemorrhage gastrointestinal bleeding urogenital bleeding among new user rivaroxaban SOC NVAF outcome analyzed using cohort rivaroxaban SOC use nested casecontrol design current v nonuse Statistical analysis comparing rivaroxaban SOC cohort performed  February  Patient characteristic new rivaroxaban user nonvalvular atrial fibrillation changed   change differed countries pattern methodological implications considered interpretation observational study comparing effectiveness safety oral anticoagulants especially regarding potential bias due unmeasured confounding  February  Page Filter Therapeutic area Type study information question suggestion services Please hesitate get touch u via button below fill contact form contact page look forward hearing you Founded  PHARMO Institute independent scientific research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources Links Navigate Contact PHARMO InstituteVan Deventerlaan  AE UtrechtThe Netherlands     pharmopharmonl use cooky ensure give best experience website continue use site assume happy it Menu Expertise expertiseThe expert PHARMO Institute perform tailormade observational research using real world data help client effectively bridge gap clinical trial data real world evidence staff consists academically trained specialist epidemiology pharmacotherapeutics medicine informatics PHARMO Institutes inhouse expert performing pharmacoepidemiological study including project management methodology data quality stakeholder communication European level perform  and many PHARMO Institute us collection management analysis inhouse data source well data source partners lead European study provide critical evidence context emerging standard study design database analysis operations quality assurance EuropePHARMO Institute adheres high standard throughout research process based robust methodologies transparency scientific independence internal standardised procedure quality guideline accordance ENCePP Guide Methodological Standards Pharmacoepidemiology ENCePP Code Conduct  guarantee high quality services use data  million person year  Patients  Practices primary secondary care  Data access time information question suggestion services Please hesitate get touch u via button below fill contact form contact page look forward hearing you Founded  PHARMO Institute independent scientific research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources Links Navigate Contact PHARMO InstituteVan Deventerlaan  AE UtrechtThe Netherlands     pharmopharmonl use cooky ensure give best experience website continue use site assume happy it Menu News See Halifax ICPE  proud Gold sponsor year look forward seeing ICPE  annual meeting weeksWe would love speak conference area expertise including Oncology Hematology Diabetes Cardiovascular Central Nervous System Respiratory Nephrology Maternal CareBe sure catch three oral presentation eight poster conferenceOral PresentationsImpact COVID Pandemic Netherlands Primary Healthcare Use Clinical Outcomes People Type  DiabetesRisk cardiovascular event exacerbation chronic obstructive pulmonary disease cohort study using PHARMO Data NetworkImpact  EU risk minimization measure revised pregnancy prevention program utilization prescribing trend valproates Utrecht UniversityPostersExploring heterogeneity result multidatabase studies example using EXACOSCV programUsing realworld general practitioner data study diagnosis management dementia rationale designSurvival drug treatment pattern patient multiple myeloma triple exposure daratumumab proteasome inhibitor immunomodulatory drugsPrevalence Risk Categories Chronic Kidney Disease without Type  DiabetesRealWorld Data Lung Cancer SafetyType  Diabetes Epidemic Trends Incidence Prevalence Vaccination utilisation pattern VACEU active safety surveillance study COVID mRNA vaccine Comirnaty five European countriesSafety JCOVDEN vaccine AdCOV S using VACEU European Healthcare Data Methods result first feasibility assessmentContact u schedule time meet u conference connect attending staff includingRon Herings DirectorJetty Overbeek PhD Head PHARMO ResearchJosine Kuiper PhD Senior Business Development ManagerEline Houben PhD Senior Research ManagerKarin Swart PhD Senior Research ManagerJesse van den Berg PhD Candidate ResearcherNaomi Boxall PhD Chief Operating OfficerBe sure stop exhibit booth  speak u get information new partnership Lumanity See soon Share article information question suggestion services Please hesitate get touch u via button below fill contact form contact page look forward hearing you Founded  PHARMO Institute independent scientific research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources Links Navigate Contact PHARMO InstituteVan Deventerlaan  AE UtrechtThe Netherlands     pharmopharmonl use cooky ensure give best experience website continue use site assume happy it Menu News PHARMO Institute Lumanity Partnering Invest new Solutions Support Enhanced Real World Data Analytics pleased announce partnership Lumanity organization dedicated accelerating optimizing access medical advancesLumanity applies incisive thinking decisive action cut complex situation deliver transformative outcome accelerate optimize access medical advances transforming data information real world insight evidence Lumanity power successful commercialization empowers patients providers payers regulator take timely decisive actionThe PHARMO Institutes service highly synergistic Lumanitys company share mission optimize patient access therapy focus demonstrating real world safety effectiveness working together PHARMO Institute Lumanity able offer global RWE capability expert based US EUDutch healthcare data one detailed RWE source world representative Western Europe rich abundant primary care data say Prof Dr Ron Herings founder director PHARMO Institute Im happy found deeply scienceoriented mission aligned international partner enable us extension Netherlands play much greater role addressing global research question facing researchersThis partnership signifies enthusiasm dedication expanding RWE space providing client deeper capability direct access patient level data add Gema Parlange Global Practice Lead RWE Lumanity great team expert across Lumanity ask right questions know partner consider whole product lifecycle understand embrace regulatory requirements look forward expanding amplifying expertise working knowledgeable RWE expert PHARMOMoving forward PHARMO Institute Lumanity continue generate evidence safety effectiveness value medicine betterment patient care EU around world plan continue collaborate expand RWE space addressing global use case pharmacoepidemiology health economics outcome research learn RWE capability collaborating Lumanity Share article information question suggestion services Please hesitate get touch u via button below fill contact form contact page look forward hearing you Founded  PHARMO Institute independent scientific research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources Links Navigate Contact PHARMO InstituteVan Deventerlaan  AE UtrechtThe Netherlands     pharmopharmonl use cooky ensure give best experience website continue use site assume happy it Menu News Myocarditis pericarditis associated SARSCoV vaccine Together colleague across Europe recently published work entitled Myocarditis pericarditis associated SARSCoV vaccines populationbased descriptive cohort nested selfcontrolled risk interval study using electronic health care data four European country Frontiers Pharmacology multicountry study used data four countries researcher studied first myopericarditis diagnosis exposure first second dose Pfizer AstraZeneca Moderna Janssen COVID vaccines study followed design populationbased cohort study nested selfcontrolled risk interval SCRI Individuals followed  end data availability  latest  million individual  women median age years included  received least one COVID vaccine dose Baseline incidence myocarditis wa low Myocarditis IRRs elevated vaccination aged  years Pfizer vaccine dos IRR   CI   CI  respectively Moderna vaccine dose  IRR   CI  effect AstraZeneca vaccine dose  could excluded IRR   CI  Pericarditis wa associated vaccination Important note absolute incidence myocarditis remains low Please read check detailed methodology results Share article information question suggestion services Please hesitate get touch u via button below fill contact form contact page look forward hearing you Founded  PHARMO Institute independent scientific research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources Links Navigate Contact PHARMO InstituteVan Deventerlaan  AE UtrechtThe Netherlands     pharmopharmonl use cooky ensure give best experience website continue use site assume happy it Menu Contact u Contact PHARMO InstituteIf question research services please hesitate get touch usThe PHARMO InstituteVan Deventerlaan  AE UtrechtThe NetherlandsT E English versionDutch version information question suggestion services Please hesitate get touch u via button below fill contact form contact page look forward hearing you Founded  PHARMO Institute independent scientific research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources Links Navigate Contact PHARMO InstituteVan Deventerlaan  AE UtrechtThe Netherlands     pharmopharmonl Menu Subscribe newsletter Subscribe newsletter Subscribe newsletter First name  Last name  Company City Email  Telephone Captcha Past Newsletters Q  Q  Q  Q  Q  information question suggestion services Please hesitate get touch u via button below fill contact form contact page look forward hearing you Founded  PHARMO Institute independent scientific research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources Links Navigate Contact PHARMO InstituteVan Deventerlaan  AE UtrechtThe Netherlands     pharmopharmonl use cooky ensure give best experience website continue use site assume happy it Menu Downloads DownloadsAnnual reportsEach year develop ourto inform healthcare provider contribute PHARMO Data Network work previous year report describes highlight previous year like recently initiated collaboration external partners Profiling Parkinsons disease ProPark Consortium Personalized Medicine Approach Alzheimers Disease ABOARD project Vaccine monitoring Collaboration Europe VACEUView annual report in Dutch information question suggestion services Please hesitate get touch u via button below fill contact form contact page look forward hearing you Founded  PHARMO Institute independent scientific research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources Links Navigate Contact PHARMO InstituteVan Deventerlaan  AE UtrechtThe Netherlands     pharmopharmonl use cooky ensure give best experience website continue use site assume happy it Menu STIZON Stichting Informatievoorziening voor Zorg en Onderzoek STIZON PHARMO Database Network created  STIZON act Trusted Third Party TTP data source PHARMO Institute STIZON authorised data provider manage process identifiable patient data STIZON collect maintains identifiable patient data retrieved various healthcare provider eg general practitioner pharmacists link data patient level PHARMO Database Network used research PHARMO Institute data depleted personal information may traced back person such date birth information question suggestion services Please hesitate get touch u via button below fill contact form contact page look forward hearing you Founded  PHARMO Institute independent scientific research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources Links Navigate Contact PHARMO InstituteVan Deventerlaan  AE UtrechtThe Netherlands     pharmopharmonl use cooky ensure give best experience website continue use site assume happy it Menu us us point lives use form medication aspirine headach vaccination resist virus antibiotic eliminate bacterial infection perhaps longer trial te fight cancer chronical disease patient bound medicine rest lives Medicines always promise do Due physical difference difference daily use medicine effect medicine vary stronglyAt PHARMO Institute studying use effectiveness side effect medicines used daily practice many years use large file data million patient investigate often medicine le effective even cause side effectsPHARMO Institute place turn need substantiated authoritative evidence scientist firstacademically trained credentialed researcher know apply appropriate research methodology realworld application situations care whats right whats relevant medical professional patient make good safe timely decision pharmaceutical products information question suggestion services Please hesitate get touch u via button below fill contact form contact page look forward hearing you Founded  PHARMO Institute independent scientific research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources Links Navigate Contact PHARMO InstituteVan Deventerlaan  AE UtrechtThe Netherlands     pharmopharmonl use cooky ensure give best experience website continue use site assume happy it Menu Vacancies VacanciesTrue mission excel interest improving patient treatment care operate entrepreneurial multidisciplinary environment specialist recruit various backgrounds including epidemiologists pharmacists medical advisors biostatisticians programmer business marketing professionals Together team brings scientific expertise healthcare market knowledge global clientsWe always looking innovative creative collaborative individual join team sound like kind exciting challenging environment seeking please explore might become part team checking current opportunity sending letter outlining motivation curriculum vitae toSee vacancy below Vacancy Dutch information question suggestion services Please hesitate get touch u via button below fill contact form contact page look forward hearing you Founded  PHARMO Institute independent scientific research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources Links Navigate Contact PHARMO InstituteVan Deventerlaan  AE UtrechtThe Netherlands     pharmopharmonl use cooky ensure give best experience website continue use site assume happy it Menu News See Halifax ICPE  proud Gold sponsor  August  PHARMO Institute Lumanity Partnering Invest new Solutions Support Enhanced  July  Myocarditis pericarditis associated SARSCoV vaccine Together colleague across Europe recently  December  DIAbetes MANagement Treatment DIAMANT Cohort DIAbetes MANagement Treatment DIAMANT Cohort  December  Realworld data HERlow metastatic breast cancer population based cohort study study  November  Complex drug use number people using medicine combination medicine increasing  November  ISPOR Europe  Vienna INTREPID Trial study PHARMO Institute  October  study describes treatment patterns lowdensity lipoprotein cholesterol LDLC level healthcare resource utilization HCRU  October  people living cancer expected number  October  PHARMO Institute ICPE Copenhagen PHARMO Institute team great time  August  Page information question suggestion services Please hesitate get touch u via button below fill contact form contact page look forward hearing you Founded  PHARMO Institute independent scientific research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources Links Navigate Contact PHARMO InstituteVan Deventerlaan  AE UtrechtThe Netherlands     pharmopharmonl use cooky ensure give best experience website continue use site assume happy it Menu Terms  condition Terms  ConditionsOFPHARMO Institute NVVan Deventerlaan  AE UtrechtThe Netherlandshereinafter referred as userArticle  DefinitionsIn present general term conditions following term used sense given below unless explicitly indicated otherwisePHARMO user general term conditionsClient user opposite partyAgreement agreement concerning provision servicesArticle  GeneralThe present term condition shall apply every offer tender agreement user client user ha declared present term condition applicable insofar party explicitly deviated present term condition writingThe present term condition shall also apply agreement user execution call service third partiesPossible deviation present general term condition shall valid provided explicitly agreed upon writingThe applicability client possible purchase condition explicitly rejectedIf one stipulation present general term condition null void declared null void stipulation present general term condition shall remain fully applicable case ensuing user client shall enter negotiation agree upon new stipulation replacing null void conditions or case may be condition declared null void whereby purpose meaning original condition shall heeded far possibleDownload complete information question suggestion services Please hesitate get touch u via button below fill contact form contact page look forward hearing you Founded  PHARMO Institute independent scientific research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources Links Navigate Contact PHARMO InstituteVan Deventerlaan  AE UtrechtThe Netherlands     pharmopharmonl use cooky ensure give best experience website continue use site assume happy it Menu Privacy policy Privacy policy Using PHARMO data use PHARMO data controlled independent Compliance Committee STIZON  PHARMO Institute Compliance Committee STIZON  PHARMO Institute consists representative participating data supplier privacy expert chairman committee study requires permission Committee Prior permission required dependent detail use data study research question data used study method used analyze data peopleorganizations commissioned study described decision Compliance Committee STIZON  PHARMO Institute based applicable legislation Netherlands eg Personal Data Protection Act Medical Treatment Contract Act Within legal framework Code Conduct Use Data Health Research important document interpretation use kind data scientific research Netherlands approved Dutch Data Protection Authority  Informed Consent soon form intervention change routine care involved study informed consent must obtained addition explicit ethical approval certified Ethical Committee must obtained If example patient enrolled studies additional test need performed context study Dutch law mandate informed consent is clear distinction analysis routinely collected data conducting study requires additional test procedures study involves additional test procedure submitted certified Ethical Review Board Netherlands information question suggestion services Please hesitate get touch u via button below fill contact form contact page look forward hearing you Founded  PHARMO Institute independent scientific research organisation dedicated study epidemiology drug utilisation drug safety health outcomes utilisation healthcare resources Links Navigate Contact PHARMO InstituteVan Deventerlaan  AE UtrechtThe Netherlands     pharmopharmonl